Hydrogen-rich saline attenuates vascular smooth muscle cell proliferation and neointimal hyperplasia by inhibiting reactive oxygen species production and inactivating the Ras-ERK1/2-MEK1/2 and Akt pathways

被引:52
作者
Chen, Yali [1 ]
Jiang, Jinyao [2 ]
Miao, Huibing [3 ]
Chen, Xingjuan [4 ]
Sun, Xuejun [5 ]
Li, Yongjun [2 ]
机构
[1] Hebei Med Univ, Hosp 3, Dept Cardiol, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 2, Dept Cardiol, Shijiazhuang 050000, Hebei, Peoples R China
[3] Hebei Med Univ, Inst Basic Med, Dept Biochem & Mol Biol, Shijiazhuang 050011, Hebei, Peoples R China
[4] Hebei Med Univ, Inst Basic Med, Dept Pharmacol, Shijiazhuang 050011, Hebei, Peoples R China
[5] Second Mil Med Univ, Fac Naval Med, Dept Diving Med, Shanghai 200433, Peoples R China
关键词
hydrogen-rich saline solution; Ras-ERK1/2-MEK1/2; vascular smooth muscle cell; ELUTING STENT IMPLANTATION; TRANSLUMINAL CORONARY ANGIOPLASTY; ISCHEMIA/REPERFUSION INJURY; BALLOON INJURY; MYOCARDIAL-ISCHEMIA; OXIDATIVE STRESS; GROWTH; RESTENOSIS; EXPRESSION; ATHEROSCLEROSIS;
D O I
10.3892/ijmm.2013.1256
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hydrogen-rich saline has been reported to prevent neointimal hyperplasia induced by carotid balloon injury. The purpose of the present study was to further investigate the molecular mechanisms underlying this phenomenon. Daily injection of a hydrogen-rich saline solution (HRSS) in rats was employed to study the effect of hydrogen on balloon injury-induced neointimal hyperplasia and the neointima/media ratio was assessed. HRSS significantly decreased the neointima area and neointima/media ratio in a dose-dependent manner. In vitro effects of hydrogen on fetal bovine serum (FBS)-induced vascular smooth muscle cell (VSMC) proliferation were also investigated. Hydrogen-rich medium (HRM) inhibited rat VSMC proliferation and migration induced by 10% FBS. FBS-induced reactive oxygen species (ROS) production and activation of intracellular Ras, MEK1/2, ERK1/2, proliferative cell nuclear antigen (PCNA), Akt were significantly inhibited by HRM. In addition, HRM blocked FBS-induced progression from the G0/G1 to the S-phase and increased the apoptosis rate of VSMCs. These results showed that hydrogen-rich saline was able to attenuate FBS-induced VSMC proliferation and neointimal hyperplasia by inhibiting ROS production and inactivating the Ras-ERK1/2-MEK1/2 and Akt pathways. Thus, HRSS may have potential therapeutic relevance for the prevention of human restenosis.
引用
收藏
页码:597 / 606
页数:10
相关论文
共 56 条
[1]  
Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
[2]  
Boullier A, 2001, ANN NY ACAD SCI, V947, P214
[3]   Cell cycle progression - New therapeutic target for vascular proliferative disease [J].
Braun-Dullaeus, RC ;
Mann, MJ ;
Dzau, VJ .
CIRCULATION, 1998, 98 (01) :82-89
[4]   Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib) [J].
Chen, ZM ;
Lee, FY ;
Bhalla, KN ;
Wu, J .
MOLECULAR PHARMACOLOGY, 2006, 69 (05) :1527-1533
[5]  
CLOWES AW, 1983, LAB INVEST, V49, P327
[6]   Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death [J].
Donovan, M ;
Cotter, TG .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1644 (2-3) :133-147
[7]   Myocardial tissue troponins T and I - An immunohistochemical study in experimental models of myocardial ischemia [J].
Fishbein, MC ;
Wang, T ;
Matijasevic, M ;
Hong, LS ;
Apple, FS .
CARDIOVASCULAR PATHOLOGY, 2003, 12 (02) :65-71
[8]   Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis [J].
Fujii, K ;
Mintz, GS ;
Kobayashi, Y ;
Carlier, SG ;
Takebayashi, H ;
Yasuda, T ;
Moussa, I ;
Dangas, G ;
Mehran, R ;
Lansky, AJ ;
Reyes, A ;
Kreps, E ;
Collins, M ;
Colombo, A ;
Stone, GW ;
Teirstein, PS ;
Leon, MB ;
Moses, JW .
CIRCULATION, 2004, 109 (09) :1085-1088
[9]   Redox control of vascular smooth muscle proliferation [J].
Griendling, KK ;
Ushio-Fukai, M .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (01) :9-15
[10]  
Grube E, 2002, Z KARDIOL S3, V91, pS44